Another study aimed to explore the practical effectiveness and safety of combined cytotoxic chemotherapy and PD-1/PD-L1 inhibitor therapy for advanced NSCLC, explicitly focusing on individuals aged 75 or older and those with a performance status of 2 or higher (117). This evidence concerns the gene CD274 and non-small cell lung carcinoma.